Back to top

Primary Manuscripts

 

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med 2015 Feb 5;372(6):509-18. PMCID: PMC4341965

 

Preventing HIV in Women - Still Trying to Find Their VOICE

Saag MS. Preventing HIV in Women - Still Trying to Find Their VOICE. N Engl J Med 2015 Feb 5;372(6):564-6.

 

Other Key Manuscripts

 

Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study

Wynne J, Muwawu R, Mubiru MC, Kamira B, Kemigisha D, Nakyanzi T, Kabwigu S, Nakabiito C, Kiweewa Matovu F; VOICE Team. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study. HIV Clin Trials 2018 Oct 27:1-7 [Epub ahead of print]

 

Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa

Abbai NS, Nyirenda M, Naidoo S, Ramjee G. Prevalent Herpes Simplex Virus-2 Increases the Risk of Incident Bacterial Vaginosis in Women from South Africa. AIDS Behav 2018 Jul;22(7):2172-2180. PMCID:PMC5871553

 

HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial

Riddler SA, Husnik M, Ramjee G, Premrajh A, Tutshana BO, Pather A, Siva S, Jeenarain N, Nair G, Selepe P, Kabwigu S, Palanee-Phillips T, Panchia R, Mhlanga F, Levy L, Livant E, Patterson K, Elharrar V, Balkus J. HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One 2017 Jun 28;12(6):e0178594. PMCID: PMC5489164

 

The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples

Livant E, Heaps A, Kelly C, Maharaj R, Samsunder N, Nhlangulela L, Karugaba P, Panchia R, Marrazzo J, Chirenje ZM, Parikh UM; VOICE Study Team. The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples. J Clin Virol 2017 Sep;94:15-21. PMCID: PMC5790424

 

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations

Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses 2017 August 1; 33(8): 778-783. PMCID: PMC5564054

 

Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial

Akello CA, Bunge KE, Nakabiito C, Mirembe BG, Fowler MG, Mishra A, Marrazzo J, Chirenje ZM, Celum C, Balkus JE. Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. J Womens Health (Larchmt) 2017 Jun;26(6):670-676. PMCID: PMC5512296

 

Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003)

Chirenje ZM, Gundacker HM, Richardson B, Rabe L, Gaffoor Z, Nair GL, Mirembe BG, Piper JM, Hillier S, Marrazzo J. Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003). Sex Transm Dis 2017 Mar;44(3):135-140. PMCID: PMC5535309

 

Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Non-use Increase at the Termination Visit?

Mensch BS, Brown ER, Liu K, Marrazzo J, Chirenje ZM, Gomez K, Piper J, Patterson K, van der Straten A. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Non-use Increase at the Termination Visit? AIDS Behav 2016 Nov;20(11):2654-2661. PMCID: PMC5354168

 

Sharing of Investigational Drug Among Participants in the Voice Trial

Moodley J, Naidoo S, Moodley J, Ramjee G. Sharing of Investigational Drug Among Participants in the Voice Trial. AIDS Behav 2016 Nov;20(11):2709-2714. PMCID: PMC5071120.

 

An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women

Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, Richardson BA, Chirenje ZM, Marrazzo JM, Baeten JM. An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. J Acquir Immune Defic Syndr 2016 Jul 1;72(3):333-43. PMCID: PMC4911322

 

Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study

van der Straten A, Brown ER, Marrazzo JM, Chirenje MZ, Liu K, Gomez K, Marzinke MA, Piper JM, Hendrix CW, MTN-003 VOICE Protocol Team for the Microbicide Trials Network. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc  2016 Feb 4;19(1):20642. PMCID: PMC4744323

 

Age-Disparate Partnerships and Risk of HIV-1 Acquisition among South African Women Participating in the VOICE Trial

Balkus JE, Nair G, Montgomery ET, Mishra A, Palanee-Phillips T, Ramjee G, Panchia R, Selepe P, Richardson BA, Chirenje ZM, et al. Age-Disparate Partnerships and Risk of HIV-1 Acquisition among South African Women Participating in the VOICE Trial. J Acquir Immune Defic Syndr 2015 Oct; 70(2): 212-17. PMCID:PMC4573287

 

Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study

Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM, Bunge K, Ramjee G, Nair G, Palanee-Phillips T, et al. Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV 2015 Jul 1;2(7):e279-e287. PMCID:PMC4491329

  

Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk - Authors' reply

Noguchi LM, Richardson BA, Balkus JE, Marrazzo JM. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk - Authors' reply. Lancet HIV 2015 Sep;2(9):e366-7.

 

Pharmacological measures of adherence and risk of HIV acquisition in the VOICE study

Dai JY, Hendrix CW, Richardson BA, Kelly C, Marzinke M, Chirenje ZM, Marrazzo JM, Brown ER. Pharmacological measures of adherence and risk of HIV acquisition in the VOICE study. J Infect Dis 2016 Feb 1;213(3):335-342. PMCID:PMC4704663

  

Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial

van der Straten A, Mayo A, Brown ER, Amico KR, Cheng H, Laborde N, Marrazzo J, Torjesen K. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS Behav 2015 May;19(5):770-83. PMCID:PMC4416998

 

Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa

White R, Chileshe M, Dawson L, Donnell D, Hillier S, Morar N, Noguchi L, Dixon D. Fostering community understanding of sufficient benefit and early stopping for a phase 2B HIV prevention clinical trial in Africa. Clin Trials 2011 Feb;8(1):103-11. PMCID:PMC3478774